O+O Alpan LLC

Fairfax, Virginia 22152

0 studies enrolling now · 18 studies all time

What they study most

Antiphospholipid (aPL)-Positive, Asthma, Autoimmune Diseases, Common Variable Immune Deficiencies, Common Variable Immunodeficiency, Fabry Disease, Gaucher Disease, Hyper-IgM Syndrome, Hyperimmunoglobulin M Syndrome, Hypogammaglobulinemia, Inflammatory Diseases, Lysosomal Storage Disorders

Studies at this site

• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication — Completed
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma — Completed
• A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication — Stopped early
• Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease — Completed
• Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients — Completed
• Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function — Completed
• Safety Study of Replagal® Therapy in Children With Fabry Disease — Completed
• Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease — Completed
• Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease — Withdrawn before enrolling
• SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease — Status unconfirmed
• Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers — Completed
• Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases — Completed
• A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria — Completed
• A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) — Completed
• Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome — Stopped early
• Investigating Lysosomal Storage Diseases in Minority Groups — Status unconfirmed
• Investigation of Immune Disorders and Deficiencies — Status unconfirmed
• Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases — Completed